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Phthalates are high-production-volume
synthetic chemicals with ubiquitous human
exposures because of their use in plastics and
other common consumer products. Globally,
more than 18 billion pounds of phthalates are
used each year, primarily as plasticizers in
flexible polyvinyl chloride (PVC) products
(Blount et al. 2000a). Di-(2-ethylhexyl)
phthalate (DEHP) is the most commonly
used plasticizer for PVC, and the production
volume of DEHP alone in 1999 was esti-
mated to be 2 million tons [Center for the
Evaluation of Risks to Human Reproduction
(CERHR) 2000]. Phthalates are found in
most PVC products including vinyl uphol-
stery, tablecloths, shower curtains, raincoats,
and soft-squeeze children’s toys. In the United
States and Canada, DEHP is no longer used
to manufacture children’s products intended
for mouthing, such as pacifiers (CERHR
2000), but it may still be found in larger toys,
especially those made in other countries.
Phthalates are used as inert ingredients in
many sprays including pesticides and many
consumer products such as cosmetics and
wood ﬁnishes (Blount et al. 2000b). Phthalates
are also used as adhesives, defoaming agents,
solvents, and lubricants [National Toxicology
Program (NTP) 1998]. DEHP is approved
for use in medical devices such as tubing,
blood bags, and dialysis equipment and is also
used to manufacture the 500 million pairs of
disposable medical examination and sterile
surgical vinyl gloves produced annually (NTP
1998). Phthalates are used to impart ﬂexibility
to plastics, but they leach from plastic prod-
ucts into the environment over time. Given
their high production volume, common use,
and widespread environmental contamina-
tion, humans are exposed to these compounds
through ingestion, inhalation, and dermal
exposure on a daily basis.
The Agency for Toxic Substances and
Disease Registry (ATSDR) estimates that the
maximum daily exposure to DEHP for the
general population is about 2 mg/day.
However, occupational and medical exposures
can reach much higher levels (ATSDR 1993).
For instance, exposure to DEHP from blood
transfusions can be as high as 250–300 mg,
equivalent to a dose of 3.5–4.3 mg/kg for an
adult weighing 70 kg (CERHR 2000).
Phthalates are diesters of o-phthalic acid with
various side chain lengths, and the toxicity of
the different congeners vary (Woodward
1988). The diester forms of these chemicals
are rapidly hydrolyzed by esterases in the gut,
liver, and blood into the monoester forms,
which are considered the ultimate toxicants
(Figure 1). A recent study by the Centers for
Disease Control and Prevention (CDC) mea-
sured phthalate monoesters in human urine,
creatinine adjusted to account for variations in
urine volume (Blount et al. 2000b). MEHP,
monoethyl phthalate (MEP), monobenzyl
phthalate (MBzP), and monobutyl phthalate
(MBP) were detected in the urine of more
than 75% of subjects tested (Blount et al.
2000b). The highest levels of MEHP in this
study (67 ppb, 192 µg/g creatinine) are con-
sistent with previous studies in occupationally
exposed individuals (Blount et al. 2000b).
The CDC study also found that women of
reproductive age had signiﬁcantly higher uri-
nary levels of MBP (46.9 µg/g creatinine)
than other sex/age groups (31.4 µg/g creati-
nine; p = 0.003) (Blount et al. 2000b). These
higher levels may be due to the fact that
dibutyl phthalate (DBP) is used in many
beauty products including perfume, lotion,
and nail polish. Thus, women have a unique
exposure proﬁle, which raises a concern about
the potential health hazards posed by such
exposures. 
Limited studies in human populations
suggest an association between phthalate
exposure and adverse reproductive health out-
comes. For example, chronic occupational
exposure to high levels of phthalates is associ-
ated with decreased rates of pregnancy and
higher rates of miscarriage in female factory
workers (Aldyreva et al. 1975). Higher urinary
phthalate levels correlated with pregnancy
complications such as anemia, toxemia, and
preeclampsia in women living near a plastics
manufacturer (Tabacova 1999). Although
occupational exposure is limited to a select
population, women have exposures to phtha-
lates in beauty and consumer products on a
daily basis. During pregnancy and delivery,
both the mother and fetus may be exposed to
DEHP through medical devices. Exposure to
the fetus in utero is a concern because some
phthalates, including DEHP and DBP, are
developmental toxicants (Mylchreest et al.
1998; Tyl et al. 1988). The Food and Drug
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Phthalates are high-production-volume synthetic chemicals with ubiquitous human exposures
because of their use in plastics and other common consumer products. Recent epidemiologic evi-
dence suggests that women have a unique exposure profile to phthalates, which raises concern
about the potential health hazards posed by such exposures. Research in our laboratory examines
how phthalates interact with the female reproductive system in animal models to provide insights
into the potential health effects of these chemicals in women. Here we review our work and the
work of others studying these mechanisms and propose a model for the ovarian action of di-(2-
ethylhexyl) phthalate (DEHP). In vivo, DEHP (2 g/kg) causes decreased serum estradiol levels,
prolonged estrous cycles, and no ovulations in adult, cycling rats. In vitro, monoethylhexyl phtha-
late (MEHP; the active metabolite of DEHP) decreases granulosa cell aromatase RNA message
and protein levels in a dose-dependent manner. MEHP is unique among the phthalates in its sup-
pression of aromatase and in its ability to activate peroxisome proliferator-activated receptors
(PPARs). We hypothesize that MEHP activates the PPARs to suppress aromatase in the granulosa
cell. MEHP-, PPARα-, and PPARγ-specific ligands all similarly decreased estradiol production
and RNA message levels of aromatase in vitro. Our model shows that MEHP acts on the granu-
losa cell by decreasing cAMP stimulated by follicle stimulating hormone and by activating the
PPARs, which leads to decreased aromatase transcription. Thus, the environmental contaminant
DEHP, through its metabolite MEHP, acts through a receptor-mediated signaling pathway to
suppress estradiol production in the ovary, leading to anovulation. Key words: aromatase, diethyl-
hexyl phthalate, estradiol, female reproductive toxicity, granulosa cells, monoethylhexyl phthalate,
phthalates, ovary, peroxisome proliferator, proliferator-activated receptors. Environ Health
Perspect 111:139–145 (2003). [Online 28 October 2002]
doi:10.1289/ehp.5658 available via http://dx.doi.org/
Research ReviewAdministration (FDA) recently issued a report
acknowledging that PVC medical devices may
be a concern to some critically ill infants
(FDA 2001). Puerto Rican girls with prema-
ture breast development (thelarche) had
higher levels of blood phthalates compared to
other girls, suggesting an association between
phthalate exposure and abnormal reproductive
development (Colón et al. 2000). 
These studies are suggestive of human
health effects, but more epidemiologic data
are needed in human populations, along with
a better mechanistic understanding of the
reproductive health effects of phthalates.
Research efforts in our laboratory examine
how phthalates interact with the female
reproductive system in animal models to pro-
vide insights into the potential health effects
of these chemicals in women. Here, we
review our work and the work of others
studying these mechanisms and propose a
model for phthalate activity and implications
of this model for human health. 
Reproductive and
Developmental Toxicity 
in Animal Models
Initial reproductive and developmental toxicity
studies on phthalates in the female rodent
involved in vivo exposure during organogene-
sis. Kaul et al. (1982) reviewed the toxic
effects of DEHP on the pregnant rodent and
fetus. Developmental toxicity of DEHP
includes reduced implantations, increased
resorptions, decreased fetal body weight, and
increased malformations. These effects are
dose dependent, with a maximal no effect
level of DEHP on mouse fetuses of 70
mg/kg/day. Tomita et al. (1986) showed that
effects of DEHP in mice depend on dose and
timing of exposure. Exposure on gestational
days 7 and 8 led to a high incidence of death
and malformations, but exposure on other
days had fewer effects (Tomita et al. 1986). In
utero exposure to DEHP causes embryotoxic
and teratogenic effects in mice and rats
(Shiota and Nishimura 1982; Tyl et al. 1988).
Several of the structurally related phtha-
late esters, including DEHP and DBP, impair
fertility of both sexes in rodents. Based on fer-
tility studies in mice, DEHP is the most
potent reproductive toxicant among the
phthalates, followed by dihexyl phthalate
(DHP), dipentyl phthalate (DPP), DBP, and
dipropyl phthalate (DPrP) (Heindel et al.
1989). Phthalates with very short (diethyl) or
very long (dioctyl) side chains are not repro-
ductive toxicants (Heindel et al. 1989). In the
male rodent, DEHP causes seminiferous
tubule atrophy and decreases testis weight,
sperm production, and testicular zinc levels
(Foster et al. 1980). These testicular effects
can lead to infertility, which has been con-
ﬁrmed in breeding studies (Lamb et al. 1987).
Like DEHP, DBP is also a testicular toxicant
and causes reproductive tract malformations
in male rats after in utero exposure (Arcadi et
al. 1998; Gray et al. 1999; Moore et al. 2001;
Mylchreest et al. 1998, 1999; Parks et al.
2000). Among the structurally related phtha-
lates, DEHP, DBP, DPP, and DHP cause
testicular atrophy and are both female and
male reproductive toxicants in rodents
(Heindel and Powell 1992). Given the well-
characterized testicular toxicity in the male,
the ovary was considered a likely target for
toxicity in the female.
Pathogenesis Studies in the
Female Rodent
Our earliest studies determined the female
reproductive toxicity of DEHP; it is the most
potent reproductive toxicant among the phtha-
lates. Initial studies in vivo demonstrated that
the ovary was a target site for DEHP and that
decreased estradiol production was a primary
functional alteration of DEHP exposure. We
determined that adult, reproductively cycling
Sprague-Dawley rats dosed in vivo with 2
g/kg DEHP had decreased serum estradiol
levels, prolonged estrous cycles, and no ovula-
tions (Davis et al. 1994a). As a result of no
ovulations, there was an absence of corpora
lutea, and follicles became cystic. The site of
estradiol production in the ovary is the pre-
ovulatory follicle. Morphometric analysis of
preovulatory follicles determined that granu-
losa cells in DEHP-treated rats were signifi-
cantly smaller than control cells. The
functional decrease in estradiol and the mor-
phologically smaller follicles suggested that
the granulosa cells of preovulatory follicles
were the target cells of DEHP in the ovary.
The pathogenesis of the lesion could then be
explained by the fact that DEHP signiﬁcantly
suppressed estradiol production in ovarian
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Figure 1. Structurally related phthalate monoesters. Diesters of o-phthalic acid are quickly metabolized in
vivo to their active metabolites, the monesters. The length and structure of the side chain is important for
toxicity. 
Figure 2. Phthalate effects on serum estradiol and estrone levels at (A) proestrus and (B) estrus. Adult 90-
day-old female Sprague-Dawley rats (n = 12 per group) were treated with corn oil vehicle or 1,000 mg/kg
of DEHP, DBP, DPP, or DBBP in corn oil given daily by gavage beginning at vaginal metestrus. Rats were
killed at vaginal proestrus (n = 6 per treatment) or estrus (n = 6 per treatment) 8 or 9 days after dosing
began, following methodology described by Davis et al. (1994a).
*Signiﬁcantly different compared to control, p <0 . 05.
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*granulosa cells, and the lowered estradiol was
insufficient to trigger an ovulatory surge of
luteinizing hormone (LH). Indeed, LH surges
in DEHP-treated rats were not detected as
long as the rats were treated with DEHP.
However, DEHP-treated rats ovulated if
stimulated with an LH-like compound, evi-
dence that suppressed estradiol was the pri-
mary toxicity in the ovary (Davis et al.
1994a). These results were consistent with
another study ﬁnding decreased estradiol pro-
duction in cultures of minced ovaries from
DEHP-treated rats in estrus (Laskey and
Berman 1993).
Because the primary functional alteration
of DEHP in adult female rats is suppression
of estradiol levels, structurally related phtha-
lates were tested for their effects on estradiol.
In vivo studies examined serum estradiol and
estrone, the primary metabolite of estradiol,
to determine whether metabolism con-
tributed to decreased serum estradiol levels, as
well as to decreased estradiol production.
Female rats were treated with 0 or 1,000
mg/kg of either DEHP, DBP, DPP, or
dibutyl benzyl phthalate (DBBP) for 8–10
days over their estrous cycle under the same
experimental conditions that were used to
examine in vivo effects of DEHP (Davis et al.
1994a). At proestrus, when estradiol levels are
normally rising, the ratio of estradiol to
estrone was significantly decreased in rats
treated with 1,000 mg/kg of either DEHP or
DBP (Figure 2A). This was due to a signifi-
cant decrease in estradiol levels and slightly
increased estrone levels in DEHP-treated
rats, whereas DBP-treated rats had signifi-
cantly increased estrone levels and only
slightly lower levels of estradiol. DBP-treated
rats also had polycystic ovaries similar to
DEHP-treated rats. There was no effect of
DPP or DBBP on serum estradiol or estrone
levels measured during proestrus. However,
estradiol to estrone ratios were increased in
DPP- and DBBP-treated animals sacrificed
at estrus (Figure 2B), although these rats
ovulated. Metabolites of the structurally
related phthalates were also tested in vitro for
their effect on the granulosa cell, the primary
source of estradiol in the female rat. MEHP,
the active metabolite of DEHP, was the only
phthalate that significantly decreased estra-
diol production in rat granulosa cells in vitro
(Figure 3) (Lovekamp and Davis 2001).
Other monoesters including monobutyl,
monoethyl, monohexyl, monomethyl, mono-
propyl, and monopentyl phthalate, had no
effect on granulosa cell estradiol production
(Lovekamp and Davis 2001). The differences
in the in vivo and in vitro studies suggest that
different phthalates have different hormonal
effects in the female rodent and likely different
organ toxicity. 
If only DEHP affected granulosa cell pro-
duction of estradiol, but both DEHP and
DBP caused cystic ovaries and altered estra-
diol to estrone ratios, the question then was
how did DBP alter estradiol levels in vivo
without affecting the ovary? Part of the
answer was revealed when Fan et al. (1988)
reported that in the liver, DBP and DEHP
induce 17β-hydroxysteroid dehydrogenase
type IV (17β-HSD IV), the enzyme that
metabolizes estradiol to estrone. These data
suggested that the altered estrogen ratios in
DBP-, DBBP-, or DPP-treated rats could be
due to induction of estradiol metabolizing
enzymes in the liver. Furthermore, the action
in different tissues was consistent with the
potency of the phthalates. For example,
DEHP, the most potent reproductive toxi-
cant, altered both granulosa cell estradiol pro-
duction and metabolism, whereas DBP
altered only estradiol metabolism. These
studies show that phthalates display multiple
effects in the female, and the key to under-
standing their toxicity lies in understanding
their speciﬁc cellular and molecular effects. 
MEHP Decreases Estradiol and
Aromatase in Granulosa Cells
To determine the molecular mechanism by
which DEHP/MEHP suppressed estradiol in
the granulosa cell, the effects of MEHP on
steroid hormone synthesis were determined in
primary cultures of rat granulosa cells. Primary
cultures of granulosa cells serve as a useful sys-
tem to study hormone production in vitro
because these cells respond to follicle stimulat-
ing hormone (FSH) by inducing steroidogenic
enzymes and differentiation (Erickson 1983).
The hormonal effects of FSH in primary cul-
ture bear striking similarities to normal bio-
chemical events in vivo (Erickson 1983; Hsueh
et al. 1984). In vivo, ovarian hormone produc-
tion is controlled by the pituitary hormones
FSH and LH, which stimulate granulosa and
thecal cells, respectively (Liu and Hsueh
1986). The gonadotropins FSH and LH bind
to speciﬁc G-protein–coupled receptor sites to
stimulate adenylate cyclase and the accumula-
tion of cAMP, which activates enzymes
involved in steroidogenesis (Hsueh et al.
1984). Cholesterol is converted to preg-
nenolone by the cholesterol side-chain cleavage
enzyme (P450scc) in both granulosa and thecal
cells. The stimulation of P450scc involves
enzyme activation by FSH-stimulated cAMP
as well as intramitochondrial movement of
cholesterol to the enzyme (Hsueh et al. 1984).
Pregnenolone is the key steroidogenic interme-
diate common to all classes of steroid hor-
mones. It is converted to progesterone by
3β-hydroxysteroid dehydrogenase-isomerase.
Progesterone is then converted to androstene-
dione by the actions of the 17α-hydroxylase
and 17,20-lyase enzyme complex, which is
present in thecal cells but not in granulosa
cells. Androstenedione is converted to testos-
terone by 17β-HSD III. Finally, testosterone
diffuses into the granulosa cell, where it is
converted to estradiol by the aromatase
enzyme (Richards 1980). Aromatase is stimu-
lated both by FSH action on granulosa cells
and by thecal androgens, the substrates for
aromatase (Daniel and Armstrong 1980;
Hillier and De Zwart 1981). 
In rat ovarian granulosa cell cultures,
MEHP (100 µM) inhibited FSH-stimulated
cAMP and progesterone production (Treinen
et al. 1990). The decrease in progesterone was
prevented by stimulators of cAMP or by
pregnenolone, the precursor of progesterone.
However, MEHP decreased estradiol produc-
tion in vitro when granulosa cells were stimu-
lated either with FSH or a nondegradable
analogue of cAMP, 8br-cAMP (Davis et al.
1994b). Therefore, the effect on estradiol was
separate from the effect on FSH-stimulated
cAMP and progesterone production in the
granulosa cell. 
Because the granulosa cell is devoid of the
17α-hydroxylase and 17,20-lyase enzyme
Review | Female reproductive toxicity of MEHP
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Figure 3. Structurally related phthalate monoesters tested in vitro for their effect on granulosa cell estradiol
production. Granulosa cells were cultured from rats stimulated in vivo with diethylstilbestrol. Cells were
supplied with FSH and testosterone and cultured for 48 hr before estradiol was measured in medium.
Estradiol was normalized to cell protein. Bars represent mean and SE in three separate experiments.
*Signiﬁcantly different compared to control, p <0 . 05.
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400 µMcomplex and requires androgens to produce
estradiol, the post-cAMP effect on estradiol
was localized to the aromatase enzyme.
MEHP decreased the maximum activity of
aromatase without acting as an enzyme
inhibitor (Davis et al. 1994b). Thus, MEHP
altered the levels or availability of aromatase in
the granulosa cell either by decreasing synthe-
sis or increasing degradation of the enzyme.
Recent studies demonstrated that MEHP
decreased aromatase RNA message and pro-
tein levels in a dose-dependent manner
(Lovekamp and Davis 2001). In contrast,
MBP had no effect on granulosa cell aro-
matase message or protein levels, consistent
with earlier studies demonstrating that MBP
had no effect on granulosa cell estradiol pro-
duction. Furthermore, MEHP was speciﬁc for
aromatase and did not decrease transcript lev-
els of the cholesterol side-chain cleavage
enzyme (P450scc) in the granulosa cell.
Treatment with an exogenous form of cAMP
for the last 24 hr of culture increased transcript
levels of P450scc above baseline. However, the
decrease in aromatase after MEHP treatment
could not be rescued by adding 8-br-cAMP
(Lovekamp and Davis 2001). These observa-
tions provide molecular evidence supporting
previous observations that MEHP suppressed
aromatase and estradiol independent of FSH-
stimulated cAMP (Davis et al. 1994b). 
PPAR Activation in Granulosa
Cells
Given that MEHP suppressed aromatase tran-
scripts independent of cAMP-related path-
ways, we examined alternative pathways that
could be responsible for the suppression of aro-
matase by MEHP. Recent studies suggest a
link between MEHP activity as a peroxisome
proliferator and its toxic effect on the granu-
losa cell (Mu et al. 2000, 2001; Rubin et al.
2000). Peroxisome proliferators exert their
effects by activating the peroxisome prolifera-
tor-activated receptors (PPARs), members of
the nuclear receptor superfamily. PPAR acts as
a heterodimer with  retinoid X Receptor
(RXR) to regulate transcription, and once acti-
vated, PPAR regulates the transcription of
genes containing speciﬁc peroxisome prolifera-
tor response elements within DNA (Corton et
al. 2000). There are three known isoforms of
PPAR, and all have been detected in the rat
ovary (Braissant et al. 1996). PPARγ is the pre-
dominant isoform in the preovulatory granu-
losa cell (Komar et al. 2001). PPARγ ligands
such as troglitazone and 15d-PGJ2 inhibit aro-
matase expression level and activity in human
breast adipose stromal cells (Rubin et al.
2000). The PPARγ ligand troglitazone also
inhibits aromatase activity and mRNA level in
cultured human ovarian granulosa cells, and
PPARγ and RXR ligands act synergistically to
inhibit aromatase in these cells (Mu et al.
2000, 2001). Maloney and Waxman (1999)
showed that MEHP activates mouse and
human PPARα and γ in a COS-1 cell-based
transient trans-activation assay.
Based on these data, we hypothesized that
MEHP decreases aromatase through activation
of PPARα and PPARγ in the rat granulosa cell.
To test this hypothesis, we first compared
MEHP-, PPARα-, and PPARγ-specific lig-
ands and found that all similarly decrease
estradiol production and RNA message levels
of aromatase in rat ovarian granulosa cells
(Lovekamp and Davis 2001; Lovekamp-Swan
et al. In press). To determine which receptor
pathway was activated by MEHP, the PPARγ
pathway was inactivated by a PPARγ-selective
antagonist and MEHP (50 µM) was added to
the cells. Under these conditions, aromatase
was only partially suppressed. Additional
experiments suggest that aromatase is not
completely suppressed because MEHP still
activates PPARα. Studies are currently in
progress to examine further the effects of
PPAR activation by MEHP.
Proposed Model in the
Granulosa Cell
We propose that DEHP/MEHP mimics the
effects of fatty acids on the granulosa cell,
beginning with the evidence that DEHP and
MEHP are ligands for fatty acid binding pro-
tein (FABP) (Kanda et al. 1990). MEHP ﬁrst
acts at the membrane to inhibit FSH-stimu-
lated cAMP production, possibly by activating
an inhibitory G-protein (Gi) (Figure 4;
Lovekamp-Swan. Unpublished data). As
MEHP diffuses into the cell, it also activates
PPARs. Although MEHP activates PPAR
receptors (Corton et al. 2000), there is no evi-
dence that MEHP directly binds to PPAR.
Thus, activation of this receptor by MEHP
occurs either through release of endogenous
fatty acids from FABPs or through a yet
unidentiﬁed intermediate factor. Activation of
both PPARα and PPARγ by MEHP in the
granulosa cell results in decreased transcription
of aromatase, the primary mechanism of its
female reproductive toxicity. Activation of both
PPARα and PPARγ also increases mRNA for
FABP in the granulosa cell (Lovekamp-Swan
et al. In press), creating more binding proteins
for PPAR activators. Decreased estradiol syn-
thesis and increased estradiol metabolism con-
tribute to suppressed estradiol levels after
MEHP treatment. 
PPARγ is a key regulator of cell differentia-
tion, and understanding that MEHP activates
PPARγ provides further insight into the female
reproductive toxicity of MEHP. We hypothe-
size that by activating PPARγ, MEHP disrupts
the critical timing of the growth and differenti-
ation of the ovarian follicle. Normally, granu-
losa cells of a preovulatory follicle respond to
basal levels of FSH by increasing cAMP and
protein kinase A, which stimulate increased
expression of aromatase. Sufficient estradiol
production during the preovulatory stage is
critical for stimulating the ovulatory surge of
LH. Aromatase is rapidly shut down after the
LH surge, both by increased degradation of
Review | Lovekamp-Swan and Davis
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Figure 4. Proposed model of MEHP action in the granulosa cell. MEHP interferes with two points of the
steroid hormone pathway. Abbreviations: ER, estrogen receptor; 17α-OHase, 17α-hydroxylase; SCC, P450
side chain cleavage enzyme. First, MEHP suppresses FSH-stimulated cAMP, possibly by inhibiting binding
of FSH to its receptor or altering activation of adenylate cyclase (Grasso et al. 1993). MEHP also activates
PPARs, possibly by release of fatty acids, endogenous activators of PPAR. The activation of either PPARα
or PPARγ decreases aromatase mRNA. PPARα activation also causes an increase in the transcript level
of 17β-HSD IV, which metabolizes estradiol to estrone. Finally, both PPARα and γ increase levels of FABP
in the cell, which is able to transport MEHP and fatty acids through the cell, delivering these ligands to the
PPAR receptors.
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FABParomatase mRNA and inhibition of transcrip-
tion (Fitzpatrick et al. 1997). PPARγ activa-
tion also causes decreased transcription of the
aromatase gene and increased turnover of its
mRNA (Mu et al. 2001) and is likely part of
the program of LH-induced luteinization.
Although aromatase is shut down during the
process of luteinization, genes such as P450scc
are constitutively expressed at high levels
(Gonzalez-Robayna et al. 1999). Likewise,
MEHP suppresses aromatase levels without
altering levels of P450scc (Lovekamp and
Davis 2001). Thus, by activating PPARγ,
MEHP advances granulosa cell differentiation
to a postovulatory phenotype without ovula-
tion actually occurring. 
PPAR-mediated effects of MEHP in the
granulosa cell are consistent with those
observed in the liver of rodents. As in the gran-
ulosa cell, the induction of 17β-HSD IV by
MEHP in the liver depends on PPARα
(Corton et al. 1997; Fan et al. 1998). Increased
conversion of estradiol to estrone in both the
liver and the granulosa cell contribute to
decreased serum estradiol levels after in vivo
DEHP treatment. Peroxisome proliferators
such as DEHP also activate expression of
FABP in the liver (Kaikaus et al. 1993; Poirier
et al. 2001). In fact, it has been suggested that
FABP acts as a gateway for PPAR agonists,
directly interacting with PPAR in the nucleus
(Wolfrum et al. 2001). The PPAR-mediated
effects of DEHP/ MEHP depend on tissue
distribution of the PPAR isoforms and the
PPAR-responsive genes in each tissue. Further
research will uncover the normal roles of the
PPAR receptors in the ovary as well as their
role in ovarian toxicity of environmental
chemicals such as DEHP.
What Does Mechanism Tell Us
about Health Effects?
Based on this model, one could predict the
effects of DEHP in different tissues based on
PPARα and PPARγ distribution and known
PPAR-mediated effects. To date, most of what
is known about the effects of PPARα and γ
comes from studies in the major tissues of
expression, the liver and adipose, respectively.
PPARα mediates the effects of peroxisome
proliferators in the liver, including induction
of peroxisomal and microsomal enzymes for
oxidation of fatty acids. PPARα is responsible
for the hepatocarcinogenic effect of DEHP, as
was shown by PPARα-deﬁcient mice, which
did not develop liver tumors when treated with
DEHP (Ward et al. 1998). It is hypothesized
that PPARα-mediated activation of metaboliz-
ing enzymes leads to oxidative stress and free
radical production. Although this response is
generally thought to contribute to the carcino-
genic effect of DEHP in the liver, it may be
causing more generalized toxicity in organs
such as the ovary. In a microarray study using
ovaries from animals treated with DEHP in
vivo, a select number of altered genes suggest
an oxidative stress response, including the aryl
hydrocarbon receptor, CYP1B1, and epoxide
hydrolase (Lovekamp-Swan. Unpublished
data). Activation of metabolizing enzymes by
PPARα also raises concern that exposure to
DEHP may increase susceptibility to other
toxicants requiring metabolic activation.
PPARγ regulates lipid and glucose homeostasis
and is responsible for the antidiabetic actions
of thiazolidinediones such as troglitazone.
PPARγ plays a critical role in adipocyte differ-
entiation, and it is likely that DEHP/MEHP
activates PPARγ in tissues other than the liver
to alter normal pathways of differentiation
(Ward et al. 1998). Alteration of differentia-
tion pathways would help explain the terato-
genic effects of DEHP because development is
a critical time for differentiation. 
Although all PPAR isoforms are detected
in the ovary (Braissant et al. 1996), their
physiological functions are not completely
understood. PPARs work together to exert
some effects (aromatase, FABP), but they also
have isoform-speciﬁc effects (17β-HSD IV).
It is important to understand why some cells
express only one PPAR isoform, while others,
such as the granulosa cell, express multiple
isoforms, and whether the different PPAR
isoforms interact with each other. Because
PPARγ is highly expressed in adipocytes,
MEHP may have effects here that have not
previously been explored. For example, could
the premature breast development in Puerto
Rican girls with high blood phthalate levels
(Colón et al. 2000) be explained by increased
adipocyte differentiation in the breast after
MEHP exposure? 
PPARγ is expressed in both human and
rodent ovary (Komar et al. 2001; Lambe and
Tugwood 1996), and MEHP stimulates the
transcriptional activity of both human and
rodent PPARγ (Maloney and Waxman 1999).
Studies in our laboratory have shown that in
granulosa cells, MEHP is similar in action to
another PPARγ activator, troglitazone.
Thiazolidinediones, such as troglitazone,
improve insulin sensitivity and have been used
as treatments for type 2 diabetes and polycys-
tic ovarian syndrome (PCOS). Not only does
troglitazone inhibit estradiol production in
granulosa cells (Mu et al. 2000), it also
inhibits androgen production in ovarian theca
cells (Schoppee et al. 2002). This is consistent
with the ﬁnding that PCOS patients treated
with troglitazone (200–400 mg) had signifi-
cantly decreased plasma concentrations of
androgens and estrogens after 3 months
(Dunaif et al. 1996). Because PCOS is charac-
terized by hyperandrogenism, suppression of
androgen production by troglitazone is effec-
tive in the treatment of this disease. It is not
known how the suppression of aromatase and
estradiol production by troglitazone relates to
the treatment of PCOS. Although troglita-
zone is now off the market due to its hepato-
toxicity, other thiazolidinediones that activate
PPARγ are currently used as antidiabetic
agents. It would be useful to study whether
any adverse effects on fertility have occurred
due to suppressed estradiol levels. Humans
may not be susceptible to the PPARα-medi-
ated carcinogenic effects of DEHP in the liver
due to a low level of PPARα expression
(Palmer et al. 1998) and to species differences
in PPARα responsiveness (Mukherjee et al.
1994). However, recent studies in mice lack-
ing the PPARα receptor show that the feto-
toxicity, teratogenicity, and testicular toxicity
of DEHP occur at least partly independently
of this isoform (Tickner et al. 2001; Ward et
al. 1998). Further study is needed to compare
the extent of PPARα versus PPARγ expression
and activation in humans and rodents. 
The structurally related phthalates present
a challenge to toxicologists faced with identify-
ing endocrine disruptors in the environment.
While DEHP acts through a PPAR-mediated
pathway to exert its effects on the female
reproductive system, other phthalates such as
DBP may activate only liver enzymes to alter
steroid metabolism. It is clear that steroid hor-
mones can be altered by several different
mechanisms, including both receptor-medi-
ated and non-receptor–mediated events. In
recent years, the focus on environmental
endocrine disruptors has led to the develop-
ment of screening assays to identify such com-
pounds. One such assay is designed to detect
activity on the estrogen receptor. However,
this assay would not identify compounds such
as MEHP that work through a different
receptor pathway to affect the endocrine sys-
tem. Zacharewski et al. (1998) tested the
estrogenic activity of eight commercial phtha-
late esters and found that only selected phtha-
lates (DBP, BBP, DHP) exhibited weak
estrogen receptor-mediated activity in some in
vitro assays at high concentrations. However,
none of the phthalates tested elicited classic in
vivo estrogenic responses. Therefore, we con-
clude that phthalates are not acting via the
estrogen receptor, but in fact act via PPAR.
Although screening assays are valuable tools, it
is important to remember that endocrine dis-
ruptors represent a vast array of compounds
with different mechanisms of action. 
How Is This Mechanism
Relevant to Humans?
Because micromolar doses of phthalates are
used for in vitro reproductive toxicity studies,
the question of dose relevance often arises. The
activation of PPARs by MEHP helps explain
why such a dose is necessary. Unlike ligands of
nuclear receptors, which bind in nanomolar
concentrations, the endogenous PPAR ligands,
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concentrations (Willson et al. 2001; Xu et al.
1999). Natural PPAR ligands are lipophilic
carboxylic acids, and the binding site of PPAR
can recognize a range of lipophilic ligands,
through relatively nonspecific hydrophobic
interactions (Willson et al. 2001; Xu et al.
1999). The question is whether humans are
exposed to phthalates at high enough concen-
trations to elicit a PPAR response. 
Based on recent studies by the CDC,
exposure to phthalate esters is widespread and
occurs at higher levels than previously antici-
pated (Blount et al. 2000b). People at risk for
reproductive toxicity of DEHP are likely to
include those exposed occupationally as well
as those exposed during medical procedures
such as dialysis or blood transfusion. Of par-
ticular concern is DEHP exposure in new-
borns, who receive among the highest doses
in the population from blood transfusions,
extracorporeal membrane oxygenation, and
respiratory therapy (Tickner et al. 2001).
Because phthalates can cross the placenta,
exposure to the developing fetus during critical
points in development is also a concern, espe-
cially if DEHP is altering receptor-mediated
differentiation pathways. It is clear that the
environmental contaminant DEHP, through
its metabolite MEHP, acts through a recep-
tor-mediated signaling pathway to alter estra-
diol production in the ovary. The pathways
leading to ovarian hormone production are
similar in rodents and humans, and it is rea-
sonable to assume that MEHP would sup-
press aromatase in the human ovary. It is
possible that MEHP has effects throughout a
woman’s life span, from in utero development
to puberty, reproductive years, and beyond.
Because women represent a unique phthalate
exposure group, further research is needed to
determine levels of exposure among women
in particular. By identifying the molecular
mechanism of MEHP, we hope to identify
molecular biomarkers of exposure. Future
mechanistic toxicology and epidemiology stud-
ies will determine to what extent human expo-
sure to phthalates impairs ovarian function and
hence, women’s health.
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